Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FeelGood vs NuuVim

FeelGood
Graded #127

Lower grade

vs+1.5999999999999943
NuuVim
Graded #101

Higher grade

The verdict

NuuVim takes it — 71.1/100 to 69.5/100, but only just.

NuuVim grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuuVim is a Texas-based DTC telehealth program offering compounded semaglutide and tirzepatide in both injectable and oral forms — oral access is uncommon here — plus limited brand-name Ozempic and Zepbound. FeelGood is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuuVim +17
80
97
Dose & formulationNuuVim +32
64
96
Clinical oversightFeelGood +37
79
42
Labs & monitoringFeelGood +3
53
50
FulfillmentFeelGood +10
71
61
Contract termsEven
55
55
FeelGood · left barNuuVim · right bar

The numbers

MetricFeelGoodNuuVim
WeighScore69.5/10071.1/100
GradeCC
Scorecard rank#127#101
SemaglutideNot disclosed$79/mo (all doses, compounded)
TirzepatideNot disclosed$133/mo (all doses, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
FeelGood

Graded #127 · C

Strengths

  • Both compounded semaglutide (GLP-1) and tirzepatide (GLP-1 + GIP) formulations available
  • Low compounded injection entry price ($149/mo) with no membership or hidden fees
  • Oral/dissolvable tablet option for needle-averse patients
  • LegitScript-certified site (seal #247923); OpenLoop Health telehealth backbone
  • Free shipping and HSA/FSA eligibility

Where it loses points

  • State availability not publicly disclosed on the site
  • Compounding pharmacy partner not named publicly ("US-certified pharmacy" only)
  • Brand-name ("Original") injections are expensive at $1,999/mo and limited in availability
NuuVim

Graded #101 · C

Strengths

  • Low compounded entry pricing — semaglutide from $79/mo, tirzepatide from $133/mo, flat all-dose pricing
  • Both injectable and oral compounded options for semaglutide and tirzepatide (oral access is uncommon)
  • LegitScript Certified and HIPAA-compliant
  • Two named compounding pharmacy partners (Hallandale Pharmacy and Pharmacy Hub), both vetted in our directory
  • Operating legal entity disclosed: NuuVim LLC, Texas governing law

Where it loses points

  • No founder, CEO, medical director, or pharmacist-in-charge named
  • Refund and cancellation policy not surfaced on the site
  • Compounded medications are not FDA-approved
  • Doesn't disclose which pharmacy fills which drug or form
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard